Navigation Links
Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 14, 2007 - CombinatoRx, Incorporated (NASDAQ: CRXX) today announced the presentation of additional data related to its immuno-inflammatory product candidates, CRx-102 and CRx-139, at the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology meeting, June 13-16, 2007 in Barcelona, Spain.

CRx-102

In a poster entitled "Inhibition of Macrophage and Chondrocyte Inflammatory Mediators by CRx-102, a Novel Synergistic Combination Drug Candidate", Fraser, et.al. further insights into the novel mechanism of action of CRx-102 were unveiled. The synergistic combination of the two agents, dipyridamole and prednisolone, was found to modulate converging intracellular signaling pathways to synergistically inhibit key inflammatory modulators and mediators (TNF-alpha, MIP-1a, RANTES, MDC, IL-6 and MMP-9) that control disease progression and contribute directly to disease pathology.

In a poster entitled "Response and State-Attainment Criteria in Hand OA: Analysis from a Placebo-Controlled Clinical Trial of CRx-102, A Novel Synergistic Combination Therapy", Kvien, et.al., reliable outcome measures to evaluate clinically meaningful benefits of CRx-102 treatment in osteoarthritis (OA) from an individual patient perspective were evaluated. CRx-102 consistently showed clinically meaningful benefit across these outcome measures and responder analyses:

-- BLISS response of individual pain of less than or equal to 20 (27% CRx-102 vs. 6% placebo, p=0.035)

-- Modified OMERACT-OARSI response (50% CRx-102 vs. 30% placebo, p=NSS)

-- AUSCAN 20/50/70 (AUSCAN 70: 23% CRx-102 vs. 3% placebo, p=0.037)

In a satellite symposium presentation, Dr. John Kirwan, of the Bristol Royal Infirmary in the UK and principal investigator in the CRx-102 phase 2a rheumatoid arthritis (RA) trial, gave a talk entitled "A Therapy Rejuvenation: Glucocorticoids in Arth
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
4. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
5. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
6. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:9/16/2014)... 16, 2014 On September 25 to 26, ... on medical design and manufacturing - MEDTEC China  - ... Expo Exhibition & Convention Center, bringing together close to ... to showcase their latest medical-grade raw materials, parts and ... week remaining for free visitor pre-registration to be completed. ...
(Date:9/16/2014)... Sept. 16, 2014 The Lupus Foundation of ... LLY ) today released results from UNVEIL: understanding the ... on the lupus journey and the challenges not only ... caregivers. The UNVEIL study, which involved over 1,000 people ... lupus has on all aspects of life including family, ...
(Date:9/16/2014)... HOUSTON , Sept. 16, 2014  DNAtrix, ... that the first patient was treated with the ... plus gamma interferon in a randomized, multicenter, open-label ... "DNAtrix, in collaboration with leading neurosurgeons ... announce the initiation of our randomized Phase Ib ...
Breaking Medicine Technology:MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... Scientists from the Barbara Ann Karmanos Cancer Institute in ... therapeutic agents used to promote bone health and inhibit resorption, ... with early stage breast cancer who take them for their ... American Society of Clinical Oncology Annual Meeting. , ...
... Abviva, Inc. (Pink Sheets: ABVV), a biomedical company engaged in ... today provided further details about worldwide patent protection for its breast ... , , ... as its independent auditor.  Abviva is working hard to regain compliance ...
Cached Medicine Technology:Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 2Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 3Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 4Abviva Engages W.T. Uniack & Co. As Independent Auditor 2
(Date:9/16/2014)... 2014 An experienced review website, ... and announced that Bluehost and HostGator.com are among ... want to purchase high quality web hosting (including ... visit their websites now. , BlueHost ( ... established itself as a reliable and long-standing force ...
(Date:9/16/2014)... Pulmonary Hypertension Association Travels to San Diego for ... Patients and Families to Help Fight Rare Lung Disease , ... pulmonary hypertension association that works to find ways to prevent ... lungs that affects the functioning of the heart and can ... only 2.8 years. , What:, PHA On The ...
(Date:9/16/2014)... (PRWEB) September 17, 2014 ... hosting suppliers from the USA and announces ... ) are the best Windows web hosting ... on offering worldwide clients high quality WordPress ... low rates. , HostMonster provides outstanding ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, 2014 ... human papillomavirus (HPV), which is linked to the risk of ... that testing urine for HPV has good accuracy when compared ... lead researcher Dr. Neha Pathak. She is a resident in ... of London, England. The test could be done at ...
(Date:9/16/2014)... Advanced Fertility Center of Texas’ Dr. ... as one of the Top Doctors of 2014. The ... metropolitan magazine serving the Houston area. They award esteemed ... their outstanding services. This accomplishment will be included in ... — a special publication listing all the winners of ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: BlueHost and HostGator.com Are Among the Best Hosting Suppliers in 2014 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 3Health News:Best Windows Web Hosting Suppliers Recommended By SEO Hosting Review Site Top10BestSEOHosting.com 2Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2
... Modifying gene called Foxp3 may develop cells capable of ... -- New understanding about how to control autoimmune responses ... arthritis (RA), British researchers say. , RA -- a ... body,s immune system attacks itself. A molecule called Foxp3 ...
... financial, operational, and clinical visibility to ... ... Fla., Nov. 13 Sentry Data Systems,today announced HealthBIT, a ... and clinical,visibility to hospitals by qualifying, aggregating, and comparing their,data ...
... Found with Free, Online Resources -, White ... paying out-of-pocket to fill prescriptions, and with those ... "Safe,Strategies for Drug Savings" today on its site ... in the U.S., Canada, and other,countries as well, ...
... Access to the Power of the Xevo TQ System,s Quantitative ... ... MILFORD, Mass., Nov. 13 Focused on the,process of helping firms ... ) will showcase innovative,UltraPerformance LC(R) (UPLC) and mass spectrometry (MS) solutions ...
... suite enables payors to compete like ... evolving healthcare marketplace, BURLINGTON, Mass., Nov. 13 ... platform for healthcare payors,today announced that it will ... 2008 Gartner Healthcare Summit. The,conference will be held ...
... Patients with advanced non-small cell lung cancer whose ... rate of tumor shrinkage and a longer interval ... standard second-line erlotinib therapy, according to a study ... Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and ...
Cached Medicine News:Health News:New Therapy Could Transform Arthritis Treatment 2Health News:Sentry Data Systems Announces Healthcare Business Intelligence Technology Platform 2Health News:PharmacyChecker.com Publishes 'Safe Strategies for Drug Savings' to Help All Americans Get Affordable Medication 2Health News:Waters To Unveil Xevo TQ MS Applications for Improved Drug Discovery at AAPS 2008 2Health News:Waters To Unveil Xevo TQ MS Applications for Improved Drug Discovery at AAPS 2008 3Health News:HealthEdge(R) Presents Award-Winning HealthRules(R) Technology Platform at the 2008 Gartner Healthcare Summit 2
80 inch PVC tubing with connectors and 19 gauge straight, beveled cannula. Fits Bausch & Lomb Surgical cassettes. Allows the safe removal of silicone oil in 10 minutes or less. 3/Box...
... gauge, 25 mm cannula with 30 gauge, 4.76 ... mm flattened tip. Cannula is attached to a ... ID x 8 inch long), for use with ... other vitreo-retinal membranes using visco elastic materials. Flattened, ...
20 gauge x 25 mm cannula with 30 degree x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub. 10 per box....
Developed for oculoplastic procedures for corneal and scleral protection. Dimensions enable protector to rest on the sclera and not on the cornea. Easily removed with Bishop-Harmon Forceps. Individua...
Medicine Products: